Journal
IMMUNOLOGICAL INVESTIGATIONS
Volume 51, Issue 1, Pages 182-198Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/08820139.2020.1817069
Keywords
Rheumatoid arthritis; 14-3-3 eta; diagnosis; meta-analysis
Categories
Funding
- National Natural Science Foundation of China [81573217, 81872693]
Ask authors/readers for more resources
This study systematically evaluated the diagnostic value of 14-3-3 eta protein for RA, and found that it is a supplementary biomarker for the diagnosis of RA.
Objective: To systematically evaluate the diagnostic value of 14-3-3 eta protein for rheumatoid arthritis (RA). Method: Searched PubMed, Web of Science, Embase and China Biology Medicine (CBM) databases comprehensively from inception to May 2020. The evaluation index were the pooled sensitivity, specificity, diagnosis odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), as well as the area under the summary receiver operating characteristic (SROC) curves. Meta-Disc 1.4 and RevMan 5.3 were used to analyze all statistics. QUADAS-2 tool was applied to evaluate the quality of eligible studies. Subgroup analysis and meta-regression were used to explore the sources of heterogeneity. Results: Nine articles containing eleven records were eligible for this meta-analysis. The pooled sensitivity of 14-3-3 eta was 0.63 (95% CI: 0.60 to 0.66), the pooled specificity was 0.90 (95% CI: 0.88 to 0.91). The pooled PLR and NLR was 6.10 (95% CI: 4.67 to 7.96) and 0.40 (95% CI: 0.33 to 0.48), respectively. The pooled DOR was 15.90 (95% CI: 11.15 to 22.68), and the area under the curve (AUC) was 0.8696. Compared with a single indicator (rheumatoid factor or anti-citrullinated protein antibodies), adding 14-3-3 eta can bring incremental benefits to the diagnosis of RA. The results of subgroup analysis and meta-regression suggested that the two factors (ethnicity, early vs established RA) we analyzed might not be the source of heterogeneity (P value were 0.0979 and 0.4298, respectively) and there was no publication bias among these articles (P = .42). Conclusion: Serum 14-3-3 eta protein is a supplementary biomarker in the diagnosis of RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available